A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PanRVD
  • Most Recent Events

    • 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Interim results (n=16) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top